Rapport Therapeutics Common Net Income
| RAPP Stock | 29.99 0.79 2.71% |
As of the 20th of February, Rapport Therapeutics holds the Coefficient Of Variation of 967.57, risk adjusted performance of 0.0869, and Semi Deviation of 3.5. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rapport Therapeutics, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Rapport Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rapport Therapeutics' valuation are summarized below:There are currently one hundred seven trending fundamental ratios for Rapport Therapeutics that can be evaluated and compared over time across competitors. Investors and active traders are advised to check out Rapport Therapeutics' recent fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. As of 02/20/2026, Market Cap is likely to grow to about 426.2 M. Also, Enterprise Value is likely to grow to about 373.4 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -70.5 M | -67 M | |
| Net Loss | -70.5 M | -74 M | |
| Net Loss | (4.34) | (4.56) | |
| Net Income Per E B T | 0.90 | 0.80 |
Rapport | Net Income | Build AI portfolio with Rapport Stock |
Evaluating Rapport Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Rapport Therapeutics Common's fundamental strength.
Latest Rapport Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Rapport Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Rapport Therapeutics financial statement analysis. It represents the amount of money remaining after all of Rapport Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Rapport Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rapport Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (78.31 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Rapport Net Income Regression Statistics
| Arithmetic Mean | (22,882,223) | |
| Coefficient Of Variation | (105.73) | |
| Mean Deviation | 18,705,046 | |
| Median | (10,652,000) | |
| Standard Deviation | 24,193,889 | |
| Sample Variance | 585.3T | |
| Range | 67.7M | |
| R-Value | (0.71) | |
| Mean Square Error | 306T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (3,421,015) | |
| Total Sum of Squares | 9365.5T |
Rapport Net Income History
Other Fundumenentals of Rapport Therapeutics
Rapport Therapeutics Net Income component correlations
Rapport Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Rapport Therapeutics is extremely important. It helps to project a fair market value of Rapport Stock properly, considering its historical fundamentals such as Net Income. Since Rapport Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rapport Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rapport Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Can Pharmaceuticals industry sustain growth momentum? Does Rapport have expansion opportunities? Factors like these will boost the valuation of Rapport Therapeutics. Anticipated expansion of Rapport directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Rapport Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
The market value of Rapport Therapeutics is measured differently than its book value, which is the value of Rapport that is recorded on the company's balance sheet. Investors also form their own opinion of Rapport Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rapport Therapeutics' true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Rapport Therapeutics' market value can be influenced by many factors that don't directly affect Rapport Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rapport Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rapport Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rapport Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Rapport Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rapport Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rapport Therapeutics.
| 11/22/2025 |
| 02/20/2026 |
If you would invest 0.00 in Rapport Therapeutics on November 22, 2025 and sell it all today you would earn a total of 0.00 from holding Rapport Therapeutics Common or generate 0.0% return on investment in Rapport Therapeutics over 90 days. Rapport Therapeutics is related to or competes with Nurix Therapeutics, Kodiak Sciences, Phathom Pharmaceuticals, Xencor, BridgeBio Oncology, AnaptysBio, and UroGen Pharma. Rapport Therapeutics is entity of United States More
Rapport Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rapport Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rapport Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.76 | |||
| Information Ratio | 0.0848 | |||
| Maximum Drawdown | 15.66 | |||
| Value At Risk | (6.01) | |||
| Potential Upside | 5.76 |
Rapport Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rapport Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rapport Therapeutics' standard deviation. In reality, there are many statistical measures that can use Rapport Therapeutics historical prices to predict the future Rapport Therapeutics' volatility.| Risk Adjusted Performance | 0.0869 | |||
| Jensen Alpha | 0.3171 | |||
| Total Risk Alpha | 0.1047 | |||
| Sortino Ratio | 0.0774 | |||
| Treynor Ratio | 0.6772 |
Rapport Therapeutics February 20, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0869 | |||
| Market Risk Adjusted Performance | 0.6872 | |||
| Mean Deviation | 2.69 | |||
| Semi Deviation | 3.5 | |||
| Downside Deviation | 3.76 | |||
| Coefficient Of Variation | 967.57 | |||
| Standard Deviation | 3.43 | |||
| Variance | 11.75 | |||
| Information Ratio | 0.0848 | |||
| Jensen Alpha | 0.3171 | |||
| Total Risk Alpha | 0.1047 | |||
| Sortino Ratio | 0.0774 | |||
| Treynor Ratio | 0.6772 | |||
| Maximum Drawdown | 15.66 | |||
| Value At Risk | (6.01) | |||
| Potential Upside | 5.76 | |||
| Downside Variance | 14.11 | |||
| Semi Variance | 12.24 | |||
| Expected Short fall | (2.62) | |||
| Skewness | (0.20) | |||
| Kurtosis | (0.16) |
Rapport Therapeutics Backtested Returns
Currently, Rapport Therapeutics Common is very steady. Rapport Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.0451, which implies the firm had a 0.0451 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Rapport Therapeutics, which you can use to evaluate the volatility of the company. Please check Rapport Therapeutics' Semi Deviation of 3.5, risk adjusted performance of 0.0869, and Coefficient Of Variation of 967.57 to confirm if the risk estimate we provide is consistent with the expected return of 0.16%. Rapport Therapeutics has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 0.51, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Rapport Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Rapport Therapeutics is expected to be smaller as well. Rapport Therapeutics right now holds a risk of 3.48%. Please check Rapport Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Rapport Therapeutics will be following its historical price patterns.
Auto-correlation | -0.31 |
Poor reverse predictability
Rapport Therapeutics Common has poor reverse predictability. Overlapping area represents the amount of predictability between Rapport Therapeutics time series from 22nd of November 2025 to 6th of January 2026 and 6th of January 2026 to 20th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rapport Therapeutics price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current Rapport Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.31 | |
| Spearman Rank Test | 0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 0.92 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Rapport Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Rapport Therapeutics Common reported net income of (78.31 Million). This is 122.94% lower than that of the Pharmaceuticals sector and 211.79% lower than that of the Health Care industry. The net income for all United States stocks is 113.71% higher than that of the company.
Rapport Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rapport Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rapport Therapeutics could also be used in its relative valuation, which is a method of valuing Rapport Therapeutics by comparing valuation metrics of similar companies.Rapport Therapeutics is currently under evaluation in net income category among its peers.
Rapport Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rapport Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rapport Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Rapport Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 830.02 M | ||||
| Shares Outstanding | 47.66 M | ||||
| Shares Owned By Insiders | 4.60 % | ||||
| Shares Owned By Institutions | 95.40 % | ||||
| Number Of Shares Shorted | 3.29 M | ||||
| Price To Book | 2.60 X | ||||
| EBITDA | (77.47 M) | ||||
| Net Income | (78.31 M) | ||||
| Total Debt | 1.48 M | ||||
| Book Value Per Share | 10.74 X | ||||
| Cash Flow From Operations | (64.83 M) | ||||
| Short Ratio | 8.93 X | ||||
| Earnings Per Share | (2.27) X | ||||
| Target Price | 51.22 | ||||
| Number Of Employees | 69 | ||||
| Market Capitalization | 1.39 B | ||||
| Total Asset | 314.93 M | ||||
| Retained Earnings | (123.75 M) | ||||
| Working Capital | 301.04 M | ||||
| Net Asset | 314.93 M |
About Rapport Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rapport Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rapport Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rapport Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Rapport Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Rapport Stock
| 0.71 | HCM | HUTCHMED China | PairCorr |
| 0.55 | ELVN | Enliven Therapeutics | PairCorr |
| 0.54 | 7XP | Organon | PairCorr |
| 0.47 | NXS | Next Science Earnings Call This Week | PairCorr |
| 0.43 | VTYX | Ventyx Biosciences | PairCorr |
The ability to find closely correlated positions to Rapport Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics Common to buy it.
The correlation of Rapport Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.